AR079555A1 - Metodos de tratamiento de la infeccion de virus de hepatitis b (hbv) y virus de hepatitis c (hcv) - Google Patents
Metodos de tratamiento de la infeccion de virus de hepatitis b (hbv) y virus de hepatitis c (hcv)Info
- Publication number
- AR079555A1 AR079555A1 ARP100104777A ARP100104777A AR079555A1 AR 079555 A1 AR079555 A1 AR 079555A1 AR P100104777 A ARP100104777 A AR P100104777A AR P100104777 A ARP100104777 A AR P100104777A AR 079555 A1 AR079555 A1 AR 079555A1
- Authority
- AR
- Argentina
- Prior art keywords
- inhibitors
- hcv
- hepatitis
- virus
- interferon alfa
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicacion 1: Un método para el tratamiento de una, infeccion viral de hepatitis B, que comprende la administracion a un sujeto humano infectado con el virus de la hepatitis B, de una cantidad terapéuticamente eficaz de: (1) o una de sus sales farmacéuticamente aceptables. Reivindicacion 16: El método de la reivindicacion 15, donde el agente terapéutico adicional se selecciona del grupo que consiste en lamivudina, adefovir, tenofovir, telbivudina, entecavir, interferon alfa-2b, interferon alfa-2a pegilado, interferon alfa 2a, interferon alfa Nl, prednisona, predinisolona, Thymalfasin«, agonistas del receptor de ácido retinoico, 4-metilumbeliferona, Alamifovir«, Metacavir«, Albuferon«, citoquinas y agonistas de receptores de tipo TolI. Reivindicacion 26: Un método para el tratamiento de una infeccion viral de hepatitis C, que comprende la administracion a un sujeto humano infectado con el virus de hepatitis C, de una cantidad terapéuticamente eficaz de (1) o una de sus sales farmacéuticamente aceptables. Reivindicacion 40: El método de la reivindicacion 26, que además comprende la administracion de un agente terapéutico adicional al ser humano. Reivindicacion 41: El método de la reivindicacion 40, donde el agente terapéutico adicional se selecciona del grupo que consiste en interferones, ribavirina o sus análogos, inhibidores de proteasa de HCV NS3, inhibidores de alfa-glucosidasa 1, inhibidores de nucleosidos o nucleotidos de HCV NS5B polimerasa, inhibidores no nucleosidos de HCV NS5B polimerasa, inhibidores de HCV NS5A, agonistas de TLR-7, inhibidores de ciclofilina e inhibidores de HCV IRES.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28915809P | 2009-12-22 | 2009-12-22 | |
| US30034010P | 2010-02-01 | 2010-02-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR079555A1 true AR079555A1 (es) | 2012-02-01 |
Family
ID=43499802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100104777A AR079555A1 (es) | 2009-12-22 | 2010-12-20 | Metodos de tratamiento de la infeccion de virus de hepatitis b (hbv) y virus de hepatitis c (hcv) |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20110150836A1 (es) |
| AR (1) | AR079555A1 (es) |
| TW (1) | TW201141484A (es) |
| WO (1) | WO2011079016A1 (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011156757A1 (en) * | 2010-06-10 | 2011-12-15 | Gilead Sciences, Inc. | Combination of anti-hcv compounds with ribavirin for the treatment of hcv |
| CN104023726A (zh) | 2011-10-21 | 2014-09-03 | 艾伯维公司 | 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333) |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| UY34402A (es) | 2011-10-21 | 2013-05-31 | Abbvie Inc | Métodos para el tratamiento de hcv |
| CN103059022A (zh) * | 2011-10-21 | 2013-04-24 | 上海壹志医药科技有限公司 | 嘌呤衍生物及其药物用途 |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| CN103360448A (zh) * | 2012-04-09 | 2013-10-23 | 南京长澳医药科技有限公司 | 美他卡韦乙醇溶剂化合物的单晶晶型，及制备方法 |
| CN103364498B (zh) * | 2012-04-10 | 2016-12-21 | 广州一品红制药有限公司 | 生物样本中美他卡韦及其代谢产物浓度的检测方法 |
| KR20230130175A (ko) | 2014-12-26 | 2023-09-11 | 에모리 유니버시티 | Ｎ4-하이드록시시티딘, 이와 관련된 유도체 및 이의 항 바이러스적 용도 |
| US20180110784A1 (en) * | 2015-04-09 | 2018-04-26 | The Regents Of The University Of California | Synthetic tlr4 and tlr7 ligands to prevent, inhibit or treat liver disease |
| CA2982704C (en) | 2015-05-08 | 2023-10-24 | F. Hoffmann-La Roche Ag | Sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection |
| US11192914B2 (en) | 2016-04-28 | 2021-12-07 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| US11697851B2 (en) | 2016-05-24 | 2023-07-11 | The Regents Of The University Of California | Early ovarian cancer detection diagnostic test based on mRNA isoforms |
| JP7013467B2 (ja) | 2016-08-29 | 2022-01-31 | エフ．ホフマン－ラ ロシュ アーゲー | ウイルス感染の治療又は予防用の７位置換スルホンイミドイルプリノン化合物 |
| JP7101663B2 (ja) | 2016-09-13 | 2022-07-15 | エフ．ホフマン－ラ ロシュ アーゲー | Ｔｌｒ７アゴニストとｈｂｖキャプシドアセンブリ阻害剤の併用療法 |
| US10494370B2 (en) * | 2017-08-16 | 2019-12-03 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor |
| WO2019060740A1 (en) * | 2017-09-21 | 2019-03-28 | Riboscience Llc | 4'-FLUORO-2'-METHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION |
| AU2018378832B9 (en) | 2017-12-07 | 2021-05-27 | Emory University | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
| WO2019155042A1 (en) | 2018-02-12 | 2019-08-15 | F. Hoffmann-La Roche Ag | Novel sulfone compounds and derivatives for the treatment and prophylaxis of virus infection |
| KR20200128414A (ko) * | 2018-02-28 | 2020-11-12 | 에프. 호프만-라 로슈 아게 | 간암의 치료 및 예방을 위한 7-치환된 설폰이미도일퓨린온 화합물 및 유도체 |
| CN113567674A (zh) * | 2020-12-09 | 2021-10-29 | 华中科技大学同济医学院附属协和医院 | WHsAg单克隆抗体作为ELISA检测试剂的应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ504800A (en) * | 1997-11-28 | 2001-10-26 | Sumitomo Pharma | 6-Amino-9-benzyl-8-hydroxy-purine derivatives and interferon inducers, antiviral agents, anticancer agents and therapeutic agents for immunologic diseases thereof |
| TW572758B (en) * | 1997-12-22 | 2004-01-21 | Sumitomo Pharma | Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives |
| KR100892614B1 (ko) * | 2001-04-17 | 2009-04-09 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | 신규 아데닌 유도체 |
| CA2497765A1 (en) * | 2002-09-27 | 2004-04-08 | Sumitomo Pharmaceuticals Co., Ltd. | 8-hydroxy substituted adenine compounds and uses thereof |
| US20050043239A1 (en) * | 2003-08-14 | 2005-02-24 | Jason Douangpanya | Methods of inhibiting immune responses stimulated by an endogenous factor |
| TWI392678B (zh) * | 2004-03-26 | 2013-04-11 | Dainippon Sumitomo Pharma Co | ９-取代-８-氧基腺嘌呤化合物 |
| BRPI0611435A2 (pt) * | 2005-05-04 | 2010-09-08 | Pfizer Ltd | derivados de 2-amido-6-amino-8-oxopurina, composições farmacêuticas, uso e processo de preparo dos mesmos |
| ES2577514T3 (es) * | 2005-08-22 | 2016-07-15 | The Regents Of The University Of California | Antagonistas de TLR |
| TW200801003A (en) * | 2005-09-16 | 2008-01-01 | Astrazeneca Ab | Novel compounds |
| US20080269240A1 (en) * | 2005-09-22 | 2008-10-30 | Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan | Novel Adenine Compound |
| WO2007034917A1 (ja) * | 2005-09-22 | 2007-03-29 | Dainippon Sumitomo Pharma Co., Ltd. | 新規なアデニン化合物 |
| TW200745114A (en) * | 2005-09-22 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
| US20090118263A1 (en) * | 2005-09-22 | 2009-05-07 | Dainippon Sumitomo Pharma Co., Ltd. | Novel Adenine Compound |
| US20090192153A1 (en) * | 2005-09-22 | 2009-07-30 | Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan | Novel adenine compound |
| EP1939200A4 (en) * | 2005-09-22 | 2010-06-16 | Dainippon Sumitomo Pharma Co | NEW ADENINE CONNECTION |
| JP2009542645A (ja) * | 2006-07-05 | 2009-12-03 | アストラゼネカ・アクチエボラーグ | Ｔｌｒ７のモジュレーターとして作用する８−オキソアデニン誘導体 |
| WO2008005555A1 (en) * | 2006-07-07 | 2008-01-10 | Gilead Sciences, Inc. | Modulators of toll-like receptor 7 |
| TW200831105A (en) * | 2006-12-14 | 2008-08-01 | Astrazeneca Ab | Novel compounds |
| PL2125792T3 (pl) * | 2007-02-19 | 2011-05-31 | Glaxosmithkline Llc | Pochodne puryny jako immunomodulatory |
| US8067413B2 (en) * | 2007-03-19 | 2011-11-29 | Astrazeneca Ab | 9-substituted-8-oxo-adenine compounds as toll-like receptor (TLR7 ) modulators |
| WO2008114006A1 (en) * | 2007-03-19 | 2008-09-25 | Astrazeneca Ab | 9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7) modulators |
| AR065784A1 (es) * | 2007-03-20 | 2009-07-01 | Dainippon Sumitomo Pharma Co | Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas. |
| WO2008114819A1 (ja) * | 2007-03-20 | 2008-09-25 | Dainippon Sumitomo Pharma Co., Ltd. | 新規アデニン化合物 |
| US8436178B2 (en) * | 2007-05-08 | 2013-05-07 | Astrazeneca Ab | Imidazoquinolines with immuno-modulating properties |
| EP2170888B1 (en) * | 2007-06-29 | 2015-04-22 | Gilead Sciences, Inc. | Purine derivatives and their use as modulators of toll-like receptor 7 |
| PE20091236A1 (es) * | 2007-11-22 | 2009-09-16 | Astrazeneca Ab | Derivados de pirimidina como immunomoduladores de tlr7 |
| WO2009151910A2 (en) * | 2008-05-25 | 2009-12-17 | Wyeth | Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer |
| UA103195C2 (uk) * | 2008-08-11 | 2013-09-25 | Глаксосмитклайн Ллк | Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань |
| GB0908772D0 (en) * | 2009-05-21 | 2009-07-01 | Astrazeneca Ab | New salts 756 |
-
2010
- 2010-12-16 US US12/970,213 patent/US20110150836A1/en not_active Abandoned
- 2010-12-16 WO PCT/US2010/060746 patent/WO2011079016A1/en active Application Filing
- 2010-12-20 TW TW099144767A patent/TW201141484A/zh unknown
- 2010-12-20 AR ARP100104777A patent/AR079555A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201141484A (en) | 2011-12-01 |
| US20110150836A1 (en) | 2011-06-23 |
| WO2011079016A1 (en) | 2011-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR079555A1 (es) | Metodos de tratamiento de la infeccion de virus de hepatitis b (hbv) y virus de hepatitis c (hcv) | |
| Rehermann et al. | Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections | |
| US7323449B2 (en) | Thionucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | |
| ES2726998T3 (es) | Análogos de nucleósidos fluorados modificados | |
| ES2651308T3 (es) | Inhibidores antisentido de HBV | |
| JP2016503800A5 (es) | ||
| AR075584A1 (es) | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. | |
| EP3370759A1 (en) | Combination therapy of an hbv capsid assembly inhibitor and an interferon | |
| JP2010503396A5 (es) | ||
| JP2015512860A5 (es) | ||
| EP2610264A3 (en) | N-[(2'r)-2'-deoxy-2'-fluoro-2'-methyl-p-phenyl-5'-uridylyl]-l-alanine 1-methylethyl ester and process for its production | |
| RU2013125713A (ru) | Пуринмонофосфатные пролекарства для лечения вирусных инфекций | |
| JP2013522302A5 (es) | ||
| Huang et al. | Recent advances in the anti-HCV mechanisms of interferon | |
| JP2015517528A5 (es) | ||
| RU2009141187A (ru) | Серосодержащие соединения как ингибиторы ns3 серинпротеазы вируса гепатита с | |
| JP2005533108A (ja) | Ｒｎａ依存性ｒｎａウイルスポリメラーゼの阻害剤としてのヌクレオシド誘導体 | |
| BR112012024923A2 (pt) | "fosforamidatos de nucleosídeo, composição, comprimido, e seus usos" | |
| JP2009504157A5 (es) | ||
| JP2011024578A (ja) | ２’−分枝ヌクレオシドおよびフラビウイルス科ウイルス突然変異 | |
| US20150329864A1 (en) | Design of oligonucleotide analogs as therapeutic agents | |
| JP2010515760A5 (es) | ||
| EP2609923A3 (en) | Nucleoside Phosphoramidates | |
| US10987372B2 (en) | Anti-hepatoma-virus agent | |
| De Clercq | Antiviral drug discovery: ten more compounds, and ten more stories (part B) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |